🚀 VC round data is live in beta, check it out!
IQVIA Valuation Multiples
Discover revenue and EBITDA valuation multiples for IQVIA and similar public comparables like Veeva, GE HealthCare, Roper Technologies, Sartorius and more.
IQVIA Overview
About IQVIA
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Founded
2016
HQ
Employees
93.0K
Website
Sectors
Financials (LTM)
EV
$43B
IQVIA Financials
IQVIA reported last 12-month revenue of $17B and EBITDA of $4B.
In the same LTM period, IQVIA generated $6B in gross profit, $4B in EBITDA, and $2B in net income.
Revenue (LTM)
IQVIA P&L
In the most recent fiscal year, IQVIA reported revenue of $16B and EBITDA of $4B.
IQVIA expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $17B | XXX | $16B | XXX | XXX | XXX |
| Gross Profit | $6B | XXX | $5B | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $4B | XXX | $4B | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | — | — | $14B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
IQVIA Stock Performance
IQVIA has current market cap of $30B, and enterprise value of $43B.
Market Cap Evolution
IQVIA's stock price is $176.46.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $43B | $30B | 0.0% | XXX | XXX | XXX | $12.32 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIQVIA Valuation Multiples
IQVIA trades at 2.6x EV/Revenue multiple, and 11.3x EV/EBITDA.
EV / Revenue (LTM)
IQVIA Financial Valuation Multiples
As of April 19, 2026, IQVIA has market cap of $30B and EV of $43B.
Equity research analysts estimate IQVIA's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IQVIA has a P/E ratio of 14.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $30B | XXX | $30B | XXX | XXX | XXX |
| EV (current) | $43B | XXX | $43B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 11.3x | XXX | 11.5x | XXX | XXX | XXX |
| EV/EBIT | 13.6x | XXX | 13.8x | XXX | XXX | XXX |
| EV/Gross Profit | 7.9x | XXX | 8.0x | XXX | XXX | XXX |
| P/E | 14.1x | XXX | 14.3x | XXX | XXX | XXX |
| EV/FCF | 20.0x | XXX | 20.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified IQVIA Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
IQVIA Margins & Growth Rates
IQVIA's revenue in the last 12 month grew by 6%.
IQVIA's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.
IQVIA's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IQVIA's rule of X is 37% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
IQVIA Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
IQVIA Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Health Data & Analytics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| IQVIA | XXX | XXX | XXX | XXX | XXX | XXX |
| Veeva | XXX | XXX | XXX | XXX | XXX | XXX |
| GE HealthCare | XXX | XXX | XXX | XXX | XXX | XXX |
| Roper Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Sartorius | XXX | XXX | XXX | XXX | XXX | XXX |
| Wuxi Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IQVIA M&A Activity
IQVIA acquired XXX companies to date.
Last acquisition by IQVIA was on XXXXXXXX, XXXXX. IQVIA acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by IQVIA
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIQVIA Investment Activity
IQVIA invested in XXX companies to date.
IQVIA made its latest investment on XXXXXXXX, XXXXX. IQVIA invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by IQVIA
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout IQVIA
| When was IQVIA founded? | IQVIA was founded in 2016. |
| Where is IQVIA headquartered? | IQVIA is headquartered in United States. |
| How many employees does IQVIA have? | As of today, IQVIA has over 93K employees. |
| Who is the CEO of IQVIA? | IQVIA's CEO is Ari Bousbib. |
| Is IQVIA publicly listed? | Yes, IQVIA is a public company listed on NYSE. |
| What is the stock symbol of IQVIA? | IQVIA trades under IQV ticker. |
| When did IQVIA go public? | IQVIA went public in 2013. |
| Who are competitors of IQVIA? | IQVIA main competitors are Veeva, GE HealthCare, Roper Technologies, Sartorius. |
| What is the current market cap of IQVIA? | IQVIA's current market cap is $30B. |
| What is the current revenue of IQVIA? | IQVIA's last 12 months revenue is $17B. |
| What is the current revenue growth of IQVIA? | IQVIA revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of IQVIA? | Current revenue multiple of IQVIA is 2.6x. |
| Is IQVIA profitable? | Yes, IQVIA is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of IQVIA? | IQVIA's last 12 months EBITDA is $4B. |
| What is IQVIA's EBITDA margin? | IQVIA's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of IQVIA? | Current EBITDA multiple of IQVIA is 11.3x. |
| What is the current FCF of IQVIA? | IQVIA's last 12 months FCF is $2B. |
| What is IQVIA's FCF margin? | IQVIA's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of IQVIA? | Current FCF multiple of IQVIA is 20.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.